Prana Biotechnology Ltd., of Melbourne, Australia, reported that further preclinical evidence for PBT-434 will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Hong Kong. The data demonstrate in the most widely accepted animal model of multiple system atrophy (MSA), a fatal neurodegenerative disease and an important form of atypical Parkinsonism, that PBT-434 prevents alpha-synuclein aggregation, preserves neurons, decreases the number of glial cell inclusions and slows motor dysfunction.